Florence

The trials here

What the 23 trials at this site are about, from their registry records.

Conditions

• Chronic myeloid leukaemia3 trials
• Coronary artery disease3 trials
• Multiple sclerosis3 trials
• Myeloproliferative neoplasms3 trials
• Stroke3 trials
• Familial hypercholesterolaemia2 trials
• Myelodysplastic syndromes2 trials
• Acute myeloid leukaemia1 trial
• Childhood cancers1 trial
• Gastric and oesophageal cancer1 trial
• Heart failure1 trial
• Hidradenitis suppurativa1 trial
• and 5 more

Phase

• Phase 311 trials
• Phase 23 trials
• Phase 1/21 trial
• Phase 41 trial

Status

• Active, not recruiting9 trials
• Completed9 trials
• Terminated3 trials
• Recruiting2 trials

Lead sponsor

• Novartis Pharmaceuticals23 trials

Running trials

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria

  NCT07229235· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population

  NCT07543419· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer

  NCT07093801· Novartis Pharmaceuticals· Source

• Active, not recruiting

  ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

  NCT06345157· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera

  NCT05548062· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

  NCT04747613· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

  NCT04208178· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  CINC424A2X01B Rollover Protocol

  NCT02386800· Phase 4· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Hidradenitis suppurativa1 recruiting

Closed trials

• Completed

  Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.

  NCT05630001· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs

  NCT04727723· Novartis Pharmaceuticals· Source

• Completed

  An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

  NCT04353492· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

  NCT04266301· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects

  NCT04129528· Phase 2· Novartis Pharmaceuticals· Source

• Terminated

  Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

  NCT04097821· Phase 1/2· Novartis Pharmaceuticals· Source

• Terminated

  A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

  NCT03946670· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

  NCT03785405· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

  NCT01784068· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  The Gilenya Pregnancy Registry

  NCT01285479· Novartis Pharmaceuticals· Source

• Completed

  LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

  NCT00680901· Phase 3· Novartis Pharmaceuticals· Source